Tag:
Takeda
Latest Headlines
Latest Headlines
Takeda shutters Bay Area R&D shop in California shakeup
Five months after Takeda announced it was formally integrating its R&D efforts in San Francisco and San Diego into a single entity, the Japanese pharma company dropped the news that it will now shutter its Bay Area ops and move its most essential staffers and technology down south into an expanded "center of excellence."
Lundbeck soars on PhIII success for blockbuster hopeful
Lundbeck shares spiked 9% this morning on the news that three late-stage studies of its new depression drug had delivered the data needed to support upcoming regulatory filings.
Takeda rebuffed (again) in long quest for FDA drug OK
Four months before Japan's Takeda will get hit with generic competition for the diabetes blockbuster Actos, the FDA has once again rebuffed the company's application to sell the experimental drug alogliptin.
Affymax banks $50M milestone on ESA drug approval
Affymax has banked a $50 million check from its partner Takeda after they won FDA approval for an anemia treatment that will now compete with Amgen for market share.
Takeda opens new drug development center in China
Japan's Takeda is adding a new drug development center in Shanghai intended to complement the international clinical work now under way in Singapore and Cambridge, MA. Both of the existing
Takeda to ax 2,800 workers, consolidate R&D in global restructuring
Four months after closing its $14 billion Nycomed buyout, Japan's Takeda says it will take an ax to its R&D operations as it sheds 2,800 employees. Most of the layoffs will occur in Europe, with
Takeda picks up a pair of cancer drugs in $310M Intellikine buyout
Takeda Pharmaceutical has a new U.S. biotech to add to its portfolio of drug developers. The pharma outfit announced this morning that it will buy out La Jolla, CA-based Intellikine and scoop up its
Affymax spikes after expert panel backs new anemia drug rival to Amgen
Shares of Affymax spiked more than 25% this morning as investors got a chance to show their enthusiasm for the big support FDA experts provided Wednesday afternoon for the biotech's experimental
Takeda unveils new vaccine business headed by Gates Foundation exec
Japan's Takeda has announced the company plans to launch a vaccine development business unit at the beginning of 2012. The new division will be headed up by Dr. Rajeev Venkayya, who's currently
Potential rival to Amgen's anemia drug faces big day with FDA advisers
Affymax ( $AFFY ) has been part of a "David and Goliath" story for years, with the small biotech developing an anemia drug called peginesatide for kidney dialysis patients that could rival Epogen, from
